（编辑 丛可心） 证券日报网讯 12月22日晚间，以岭药业发布公告称，公司2025年第二次临时股东大会审议通过《关于 修改的议案》《关于制定、修订公司部分治理制度的议案》《关于募集资金投资项目结项并将节余募集 资金永久补充流动资金的议案》等多项议案。 ...

Group 1 - The core viewpoint of the article is that Yiling Pharmaceutical (002603) has passed several important resolutions during its second extraordinary general meeting of shareholders in 2025 [1] - The company approved the proposal to amend its Articles of Association [1] - The company also approved the proposal to formulate and revise certain governance systems [1] - Additionally, the company resolved to conclude fundraising investment projects and permanently supplement the remaining raised funds into working capital [1]

证券代码：002603 证券简称：以岭药业 公告编号：2025-053 石家庄以岭药业股份有限公司 2025 年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形； 2、本次股东大会没有涉及变更前次股东大会决议。 一、会议召开和出席情况 （一）会议召开情况： 1、会议召开时间： （1）现场会议时间：2025 年 12 月 22 日下午 14:50 （2）网络投票时间：2025 年 12 月 22 日。其中，通过深圳证券交易所交易 系统进行网络投票的时间为 2025 年 12 月 22 日上午 9:15—9:25，9:30—11:30， 下午 13:00—15:00；通过深圳证券交易所互联网投票系统投票的具体时间为 2025 年 12 月 22 日 9:15 至 15:00 的任意时间 2、会议地点：石家庄高新区天山大街 238 号以岭健康城会议室 3、会议召开方式：现场投票、网络投票相结合 4、会议召集人和主持人：公司董事会。董事长吴相君先生主持会议。 本次会议的召集、召开程序及表决方式 ...

北京市东城区建国门内大街 26 号新闻大厦 7 层、8 层 电话：010-88004488/66090088 传真：010-66090016 邮编：100005 北京国枫律师事务所 关于石家庄以岭药业股份有限公司 2025 年第二次临时股东大会的 法律意见书 国枫律股字[2025]A0622 号 致：石家庄以岭药业股份有限公司（贵公司） 北京国枫律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出席并见 证贵公司 2025 年第二次临时股东大会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下简称 "《股东会规则》"）、《律师事务所从事证券法律业务管理办法》（以下简称"《证券法律 业务管理办法》"）、《律师事务所证券法律业务执业规则（试行）》（以下简称"《证券法 律业务执业规则》"）等相关法律、行政法规、规章、规范性文件及《石家庄以岭药业股 份有限公司章程》（以下简称"《公司章程》"）的规定，就本次会议的召集与召开程序、 召集人资格、出席会议人员资格、会议表决程序及表决结果等事宜， ...

Group 1 - The core point of the announcement is that the actual controller of Shijiazhuang Yiling Pharmaceutical Co., Ltd., Wu Rui, has notified the company about the extension of the pledge on part of her shares [1] - The announcement details the basic situation of the shareholder's share pledge extension, indicating that Wu Rui's credit status is good and she has a strong repayment ability, thus the pledge risk is controllable [1] - The pledged shares will not lead to a change in the company's actual control, nor will it affect the company's production operations and governance [1] Group 2 - As of the announcement date, the cumulative situation of pledged shares held by the shareholder and their concerted actions is provided, indicating that the pledged shares are subject to restrictions due to being locked-up shares for executives [1] - In case of any risk of forced liquidation, Wu Rui will take measures such as additional pledges or early repurchase of the pledged shares to mitigate risks [1]

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：002603 证券简称：以岭药业 公告编号：2025-052 石家庄以岭药业股份有限公司 关于实际控制人部分股份质押展期的公告 石家庄以岭药业股份有限公司（以下简称"公司"或"本公司"）于2025年12月 19日接到公司实际控制人吴瑞的通知，获悉吴瑞所持有本公司的部分股份办理质 押展期，具体事项如下： 一、股东部分股份质押展期的基本情况 | 股东名 | 是否为控股 股东或第一 | 本次质押展 | 占其所 | 占公司 | 是否为 | 是否为补 | 原质押起 | | 展期后到 | | 质押 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 称 | 大股东及其 | 期数量（股） | 持股份 | 总股本 | 限售股 | 充质押 | 始日 | | 期日 | 质权人 | 用途 | | | 一致行动人 | | 比例 | 比例 | | | | | | | | | 吴瑞 | 公司实际控 | 2,600,000 | 6 ...

截至发稿，以岭药业市值为293亿元。 每经AI快讯，以岭药业（SZ 002603，收盘价：17.56元）12月19日晚间发布公告称，公司接到公司实际 控制人吴瑞的通知，获悉吴瑞所持有本公司的部分股份办理质押展期，本次质押展期股份726万股。截 至本公告日，吴相君累计质押股数为1500万股，占其所持股份比例为4.31%。吴瑞累计质押股数为899 万股，占其所持股份比例为22.99%。 每经头条（nbdtoutiao）——海南封关首日直击：为中国探路，全球最大自贸港如何重塑开放边界？ 2025年1至6月份，以岭药业的营业收入构成为：医药制造业占比100.0%。 （记者 王晓波） ...

Group 1 - The core viewpoint of the article highlights that Yiling Pharmaceutical has been recognized as an outstanding innovative enterprise in traditional Chinese medicine at the 2025 Jiemian Finance Annual Conference, emphasizing its commitment to R&D innovation [1] - Yiling Pharmaceutical's R&D expenses reached 544 million yuan in the first three quarters of 2025, accounting for 9.27% of its operating revenue, indicating a strong focus on research and development [1] - The company has invested over 5 billion yuan in R&D from 2019 to 2024, maintaining a leading position in the industry [1] Group 2 - Yiling Pharmaceutical's innovative efforts have led to the approval and successful registration of its traditional Chinese medicine, Qifang Nasal Congestion Tablets, as the first registered innovative Chinese medicine in Macau [1] - The company has launched 17 patented traditional Chinese medicines targeting major diseases such as cardiovascular, respiratory, and endocrine disorders, showcasing a diverse product portfolio [1] - Several new traditional Chinese medicines, including Qigui Lobotomy Tablets and Children's Lianhua Qinggan Granules, are in the application or clinical research stages, indicating a rich pipeline of R&D reserves [1][3]

Investment Rating - The industry rating is maintained at "Overweight" [6] Core Insights - The Chinese medicine sector experienced a significant decline, with the Chinese medicine index dropping by 2.03% last week, while other pharmaceutical sub-sectors also faced declines, except for medical services which saw a 1.67% increase [1][19] - The price-to-earnings (PE) ratio for the Chinese medicine sector is 27.17X, down by 0.55X week-on-week, while the price-to-book (PB) ratio is 2.29X, down by 0.04X week-on-week [2] - The demand for flu-related and tonic herbs has increased, leading to a rise in the price index of Chinese medicinal materials, which is expected to continue to rise slightly in the future [3] - The national medical insurance work conference highlighted the restructuring of prices and market patterns as a major direction for the Chinese medicine industry in 2026, emphasizing the importance of collective procurement and support for innovation in the industry [4][9] Summary by Sections Market Performance - The Chinese medicine index closed at 6372.09 points, down 2.03% last week, with only the medical services sector recording positive returns [1][19] Valuation - The current PE ratio for the Chinese medicine sector is 27.17X, with a year-high of 30.26X and a year-low of 24.72X, placing it at the 28.41% percentile since 2013 [2] Supply Chain Insights - The price index for Chinese medicinal materials rose to 225.57 points, a 0.4% increase from the previous week, driven by increased demand due to the flu outbreak and winter tonic herbs [3] Policy and Market Trends - The 2026 direction for the Chinese medicine industry includes continued promotion of collective procurement and support for innovation, with an emphasis on price governance and market restructuring [4][10] - The focus on long-term care insurance is expected to increase demand for Chinese medicine products, particularly in the context of an aging population [9] Investment Recommendations - The report suggests focusing on three main investment themes: price governance, consumption recovery, and state-owned enterprise reform, with specific recommendations for companies with strong R&D capabilities and unique products [10][11]

Core Viewpoint - The rising demand for travel protection due to respiratory diseases has led to a collaboration between Yiling Health and Shenzhou Car Rental, launching the "New Year Journey" campaign to provide health products for users during year-end travel [1] Group 1: Product Offerings - The campaign features the Lianhua Respiratory Health product series, which utilizes the patented Lianhua HAbO essential oil to create a comprehensive protective system [1] - The Lianhua mask bead, praised as an "air renewal artifact" for in-car protection, releases essential oil upon squeezing, alleviating discomfort from prolonged mask use [2] - Additional products include the Lianhua throat spray for soothing, Lianhua sugar-free herbal candy for throat relief, and Lianhua plant beverage for hydration, all aimed at enhancing travel comfort [2] Group 2: Market Positioning - Yiling Health aims to meet diverse travel needs across various demographics, including commuters and students, by providing a health barrier through its product offerings [4] - The company plans to continue focusing on consumer protection needs in different life scenarios, integrating traditional Chinese medicine with modern technology for respiratory health [4] - The comprehensive protective logic of the Lianhua Respiratory Health series is designed to ensure safe and healthy travel experiences for users [4]